EMA Authorised: Vipdomet (alogliptin benzoate;metformin hydrochloride) — Takeda Pharma A/S

View source ↗

Summary

European Medicines Agency authorised Vipdomet, a fixed-dose combination of alogliptin benzoate and metformin hydrochloride, for the treatment of Type 2 diabetes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Vipdomet (alogliptin benzoate; metformin hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Takeda Pharma A/S. Decision date: 19/05/2025